查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
mRNA疫苗市場 - 2018-2028年全球行業規模、佔有率、趨勢、機會和預測，按 mRNA 類型、應用、地區和競爭細分
市場調查報告書
商品編碼
1321045

mRNA疫苗市場 - 2018-2028年全球行業規模、佔有率、趨勢、機會和預測，按 mRNA 類型、應用、地區和競爭細分

mRNA Vaccine Market- Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By mRNA Type, By Application, Region and Competition
出版日期: | 出版商: TechSci Research | 英文 112 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

由於 mRNA 疫苗在生產、安全性、有效性和分銷等方面相對於 DNA 疫苗具有多種優勢，全球 mRNA 疫苗市場將在預測期內以驚人的速度成長。全球 mRNA 疫苗市場受到癌症、遺傳異常和病毒感染發病率上升的推動。2020年，癌症導致約 1000 萬人死亡，即近六分之一的死亡，使其成為全球最主要的死因之一。 TAA（腫瘤相關抗原）、TSA（腫瘤特異性抗原）及其相關細胞因子都可以由mRNA疫苗編碼和表達，構成了一類重要的癌症疫苗。這些疫苗更適合各種疾病和患者，因為 mRNA 癌症疫苗可以增強體液和細胞免疫。此外，COVID-19大流行的突然爆發和蔓延以及Moderna和Pfizer- BioNTech針對COVID-19疫苗的成功預計將為未來幾年mRNA疫苗市場的成長創造新的前景。這又促使許多生物技術和製藥公司以及學術研究機構挺身而出，開始研發和開展不同類型mRNA疫苗的臨床試驗，為全球mRNA疫苗的成長創造了豐厚的機會。預測期內的市場。根據 ClinicalTrials.gov 的資料，大約 444 項與 mRNA 疫苗相關的臨床研究正處於不同的開發階段，在全球不同地區進行。

mRNA疫苗的優點

與大多數疫苗的生產相比，mRNA 疫苗的生產比其他同類疫苗具有優勢，因為它不需要使用細胞培養物。由於反應時間快，污染的風險比其他複雜的疫苗生產技術要小。此外，mRNA 疫苗由於其非整合性和細胞內短暫表達而更安全。 mRNA 疫苗利用脂質封裝或裸露形式的序列最佳化 mRNA，在流感病毒、寨卡病毒、狂犬病病毒等動物模型中產生了針對傳染病靶標的有效免疫力，特別是近年來。

增加生產 mRNA 疫苗的研究活動

與其他治療方式相比，mRNA 具有眾多優勢，例如更高的生物功效、更強的免疫原性以及低毒性水準的多功能遞送平台，是該領域進行的研究和開發工作的主要驅動力。開發基於 mRNA 的疫苗來預防糖尿病、愛滋病毒、癌症和心血管疾病等傳染病或慢性疾病是廣泛研究的主題。目前有 430 項臨床試驗使用 mRNA 疫苗來預防除 COVID-19 以外的疾病。根據 ClinicalTrials.gov 的分析，大多數臨床試驗是在美國進行的。

賓夕法尼亞大學佩雷​​爾曼醫學院的研究人員研製出了一種基於 mRNA 的多價疫苗，可以預防所有20 種已知的流感病毒亞型。他們採用了與早期嘗試創建通用流感疫苗不同的方法，即包含每種亞型特有的抗原，而不僅僅是亞型共享的較小的一組抗原。輝瑞和 Moderna 生產的 SARS-CoV-2 疫苗使用了與該策略相同的 mRNA 技術。 Penn 是開發用於 COVID-19 疫苗的 mRNA 技術的領導者。

市場細分

全球 mRNA 疫苗市場可以按 mRNA 類型、應用和地區進行細分。根據mRNA類型，市場可分為核苷修飾mRNA、未修飾mRNA和自擴增mRNA。根據應用，市場分為 COVID-19 mRNA 疫苗、非 COVID-19 mRNA 疫苗等。從地區來看，mRNA疫苗可分為北美、歐洲、亞太地區、南美、中東和非洲。

市場參與者

Arcturus Therapeutics Holdings Inc., BioNTech SE, CureVac N.V., Daiichi Sankyo Company Limited., Ethris GmbH, GlaxoSmithKline plc, Gennova Biopharmaceuticals Ltd, Moderna, Inc., Pantherna Therapeutics GmbH, Providence Therapeutics, Silence Therapeutics, Translate Bio, VERSAMEB AG, Verve Therapeutics Inc. 是全球 mRNA 疫苗市場的一些領先參與者。

可用的客製化

根據給定的市場資料，TechSci Research 可根據公司的具體需求提供客製化服務。本報告可以使用以下自定義選項：

公司資訊

  • 其他市場參與者（最多五個）的詳細分析和概況分析。

目錄

第1章：產品概述

  • 市場定義
  • 市場範圍
    • 涵蓋的市場
    • 研究年份
    • 主要市場細分

第2章：研究方法

  • 研究目的
  • 基線方法
  • 主要行業合作夥伴
  • 主要協會和二手資料來源
  • 預測方法
  • 資料三角測量和驗證
  • 假設和限制

第3章：執行摘要

  • 市場概況
  • 主要市場細分概述
  • 主要市場參與者概述
  • 重點地區/國家概況
  • 市場促進因素、挑戰、趨勢概述

第4章：臨床試驗分析

  • 進行的臨床試驗
  • 已完成的臨床試驗
  • 終止的臨床試驗
  • 按開發階段分類的管道細分
  • 按狀態分類的管道細分
  • 按研究類型分類的管道細分
  • 按地區分類的管道細分
  • 臨床試驗熱圖

第5章：客戶之聲

第6章：全球 mRNA 疫苗市場展望

  • 市場規模及預測
    • 按價值
  • 市場佔有率及預測
    • 按 mRNA 類型（核苷修飾 mRNA、未修飾 mRNA、自擴增 mRNA）
    • 按應用（COVID-19 mRNA 疫苗、非 COVID-19 mRNA 疫苗、其他）
    • 按地區（北美、歐洲、亞太地區、南美、中東和非洲）
    • 按公司分類 (2022)
  • 產品圖
    • 按 mRNA 類型
    • 按申請
    • 按地區

第7章：北美 mRNA 疫苗市場展望

  • 市場規模及預測
    • 按價值
  • 市場佔有率及預測
    • 按 mRNA 類型（核苷修飾 mRNA、未修飾 mRNA、自擴增 mRNA）
    • 按應用（COVID-19、非 COVID-19、其他）
    • 按國家/地區
  • 北美：國家分析
    • 美國
    • 加拿大
    • 墨西哥

第8章：歐洲 mRNA 疫苗市場展望

  • 市場規模及預測
    • 按價值
  • 市場佔有率及預測
    • 按 mRNA 類型（核苷修飾 mRNA、未修飾 mRNA、自擴增 mRNA）
    • 按應用（COVID-19、非 COVID-19、其他）
    • 按國家/地區
  • 歐洲：國家分析
    • 法國
    • 德國
    • 英國
    • 義大利
    • 西班牙

第9章：亞太地區 mRNA 疫苗市場展望

  • 市場規模及預測
    • 按價值
  • 市場佔有率及預測
    • 按 mRNA 類型（核苷修飾 mRNA、未修飾 mRNA、自擴增 mRNA）
    • 按應用（COVID-19、非 COVID-19、其他）
    • 按國家/地區
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第10章：南美 mRNA 疫苗市場展望

  • 市場規模及預測
    • 按價值
  • 市場佔有率及預測
    • 按 mRNA 類型（核苷修飾 mRNA、未修飾 mRNA、自擴增 mRNA）
    • 按應用（COVID-19、非 COVID-19、其他）
    • 按國家/地區
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第11章：中東和非洲mRNA疫苗市場展望

  • 市場規模及預測
    • 按價值
  • 市場佔有率及預測
    • 按 mRNA 類型（核苷修飾 mRNA、未修飾 mRNA、自擴增 mRNA）
    • 按應用（COVID-19 mRNA 疫苗、非 COVID-19 mRNA 疫苗、其他）
    • 按國家/地區
  • MEA：國家分析
    • 南非 mRNA 疫苗
    • 沙烏地阿拉伯 mRNA 疫苗
    • 阿拉伯聯合大公國 mRNA 疫苗

第12章：市場動態

  • 促進因素
  • 挑戰

第13章：市場趨勢與發展

  • 最近的發展
  • 併購
  • 產品發布

第14章：全球 mRNA 疫苗市場：SWOT 分析

第15章：波特的五力分析

  • 行業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 客戶的力量
  • 替代產品的威脅

第16章：競爭格局

  • 商業概覽
  • 產品供應
  • 最近的發展
  • 財務（據報導）
  • 主要人員
  • SWOT分析
    • Arcturus Therapeutics Holdings Inc.
    • BioNTech SE
    • CureVac NV
    • Daiichi Sankyo Company Limited.
    • Ethris GmbH
    • GlaxoSmithKline plc
    • Gennova Biopharmaceuticals Ltd
    • Moderna, Inc.
    • Pantherna Therapeutics GmbH
    • Providence Therapeutics
    • Silence Therapeutics
    • Translate Bio
    • VERSAMEB AG
    • Verve Therapeutics Inc.

第17章：戰略建議

簡介目錄
Product Code: 14521

Global mRNA vaccine market is poised to grow at an impressive rate during the forecast period on account of the various benefits of mRNA vaccine over DNA vaccine in terms of production, safety, efficacy, and distribution, among others. Global mRNA Vaccine Market is driven by the rising incidence of cancer, genetic abnormalities, and viral infections. Approximately 10 million deaths, or nearly one in six deaths, happened due to cancer in 2020, making it one of the top causes of death globally. TAA (tumor-associated antigens), TSA (tumor-specific antigens), and their related cytokines can all be encoded and expressed by mRNA vaccines, which constitute a significant class of cancer vaccines. These vaccines are more adaptable to various diseases and patients because mRNA cancer vaccines can boost both humoral and cellular immunity. Besides, the sudden outbreak and spread of the COVID-19 pandemic and the success of Moderna's and Pfizer- BioNTech's vaccines against COVID-19 are expected to create new prospects for growth of the mRNA vaccine market in the coming years. This has, in turn, resulted in many biotechnology & pharmaceutical companies and academic & research institutions coming forward and starting research and development and launching clinical trials for the development of different types of mRNA vaccines, thereby creating lucrative opportunities for the growth of global mRNA vaccine market during the forecast period. According to clinicaltrials.gov, around 444 clinical studies related to mRNA Vaccines are in different phases of development being conducted across different parts of the globe.

The important reason for encouraging extensive study and deployment of mRNA vaccines is their numerous distinctive benefits. One of the main causes for the development of mRNA vaccines is their convenience of production. Simple in form, its active component, RNA, is often produced in vitro utilizing linear DNA as a template. Through codon optimization, nucleoside modification, and an additional delivery method, the stability and translation efficiency of mRNA can be enhanced during this process to create a nucleic acid vaccine with high specificity and resilient stability. The vaccine's safety is another important aspect that encourages widespread use. There is no potential risk of infection or genetic damage because the mRNA does not integrate into the host genome.

mRNA vaccines create proteins that cause human bodies to generate an immune response. Since these vaccines don't involve live viruses, there is absolutely no risk of getting sick after receiving them. The body quickly breaks down mRNA, and cells don't readily take up foreign mRNA. Recent technological advancements have improved the stability of the mRNA molecule and wrapped the molecules in lipids to improve cell delivery effectiveness. These developments boost the production of spike protein in your cells, triggering a stronger immunological response.

Furthermore, owing to recent technological developments in enhanced translation, stability, and delivery methods, messenger RNAs have emerged as a promising therapeutic tool. In fact, mRNA vaccines have opened the door to new pharmacological fields and have become a significant therapeutic class. The development of vaccines is entering a new age because of these mRNA vaccines, which support next-generation vaccinations.

Industry expansion is anticipated to be supported during the projected time by increased investments in the development of cutting-edge and efficient mRNA vaccines. For instance, American mRNA therapeutic developer Arcturus Therapeutics established a Japanese company in Chiba Prefecture in April 2021 as part of a joint venture with Axcelead, Inc., and is currently building a production plant in Minamisoma City, Fukushima Prefecture. In the upcoming years, such investments are probably going to supplement market expansion.

Advantages of mRNA Vaccines

mRNA vaccine production has advantages over the other counterparts, when compared to the production of most vaccines, since it does not require the use of cell cultures. The risk of contamination is smaller than what is seen with other sophisticated vaccine manufacturing techniques because of its quick reaction time. Additionally, mRNA vaccines are safer due to their non-integrative nature and transitory expression within cells. Using lipid-encapsulated or naked forms of sequence-optimized mRNA, mRNA vaccines have produced potent immunity against infectious disease targets in animal models of influenza virus, Zika virus, rabies virus, and others, particularly in recent years.

Increasing Research Activities to produce mRNA-based Vaccines

The numerous benefits mRNA offers over other therapeutic modalities, such as higher biological efficacy, enhanced potent immunogenicity, and versatile delivery platforms at low toxicity levels, are the main drivers of the ongoing research and development efforts being made in this field. The development of mRNA-based vaccines to prevent infectious or chronic diseases like diabetes, HIV, cancer, and cardiovascular diseases is the subject of extensive research. There are currently 430 clinical trials using mRNA vaccines to prevent diseases other than COVID-19. The majority of these clinical trials, according to an analysis by Clinicaltrials.gov, are conducted in the United States.

A multivalent, mRNA-based vaccine that protects against all 20 known influenza virus subtypes has been created by researchers at the Perelman School of Medicine at the University of Pennsylvania. They take a different approach from earlier attempts to create a universal flu vaccine by including antigens unique to each subtype rather than just a smaller set of antigens shared by subtypes. The SARS-CoV-2 vaccines made by Pfizer and Moderna used the same mRNA technology as this strategy. Penn was a leader in the development of the mRNA technology used in those COVID-19 vaccines.

Market Segmentation

Global mRNA Vaccine Market can be segmented by mRNA type, by application, and by region. Based on mRNA type, the market can be divided into nucleoside-modified mRNA, unmodified mRNA, and self-amplifying mRNA. Based on application the market is divided into COVID-19 mRNA Vaccines, Non COVID-19 mRNA Vaccines, and others. Regionally, the mRNA Vaccine can be categorized into North America, Europe, Asia Pacific, South America, and Middle East & Africa.

Market Players

Arcturus Therapeutics Holdings Inc., BioNTech SE, CureVac N.V., Daiichi Sankyo Company Limited., Ethris GmbH, GlaxoSmithKline plc, Gennova Biopharmaceuticals Ltd, Moderna, Inc., Pantherna Therapeutics GmbH, Providence Therapeutics, Silence Therapeutics, Translate Bio, VERSAMEB AG, Verve Therapeutics Inc., are some of the leading players operating in the Global mRNA Vaccine Market.

Report Scope

In this report, Global mRNA Vaccine Market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:

Global mRNA Vaccine Market, By mRNA Type:

  • Nucleoside-modified mRNA
  • Unmodified mRNA
  • Self-Amplifying mRNA

Global mRNA Vaccine Market, By Application:

  • COVID-19 mRNA Vaccines
  • Non COVID-19 mRNA Vaccines
  • Others

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in Global mRNA Vaccine Market.

Available Customizations

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Clinical Trial Analysis

  • 4.1. Ongoing Clinical Trials
  • 4.2. Completed Clinical Trials
  • 4.3. Terminated Clinical Trials
  • 4.4. Breakdown of Pipeline, By Development Phase
  • 4.5. Breakdown of Pipeline, By Status
  • 4.6. Breakdown of Pipeline, By Study Type
  • 4.7. Breakdown of Pipeline, By Region
  • 4.8. Clinical Trials Heat Map

5. Voice of Customer

6. Global mRNA Vaccine Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By mRNA Type (Nucleoside-modified mRNA, Unmodified mRNA, Self-Amplifying mRNA)
    • 6.2.2. By Application (COVID-19 mRNA Vaccines, Non COVID-19 mRNA Vaccines, Others)
    • 6.2.3. By Region (North America, Europe, Asia Pacific, South America, Middle East & Africa)
    • 6.2.4. By Company (2022)
  • 6.3. Product Map
    • 6.3.1. By mRNA Type
    • 6.3.2. By Application
    • 6.3.3. By Region

7. North America mRNA Vaccine Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By mRNA Type (Nucleoside-modified mRNA, Unmodified mRNA, Self-Amplifying mRNA)
    • 7.2.2. By Application (COVID-19 mRNA Vaccines, Non COVID-19 mRNA Vaccines, Others)
    • 7.2.3. By Country
  • 7.3. North America: Country Analysis
    • 7.3.1. United States mRNA Vaccine Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By mRNA Type
        • 7.3.1.2.2. By Application
    • 7.3.2. Canada mRNA Vaccine Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By mRNA Type
        • 7.3.2.2.2. By Application
    • 7.3.3. Mexico mRNA Vaccine Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By mRNA Type
        • 7.3.3.2.2. By Application

8. Europe mRNA Vaccine Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By mRNA Type (Nucleoside-modified mRNA, Unmodified mRNA, Self-Amplifying mRNA)
    • 8.2.2. By Application (COVID-19 mRNA Vaccines, Non COVID-19 mRNA Vaccines, Others)
    • 8.2.3. By Country
  • 8.3. Europe: Country Analysis
    • 8.3.1. France mRNA Vaccine Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By mRNA Type
        • 8.3.1.2.2. By Application
    • 8.3.2. Germany mRNA Vaccine Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By mRNA Type
        • 8.3.2.2.2. By Application
    • 8.3.3. United Kingdom mRNA Vaccine Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By mRNA Type
        • 8.3.3.2.2. By Application
    • 8.3.4. Italy mRNA Vaccine Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By mRNA Type
        • 8.3.4.2.2. By Application
    • 8.3.5. Spain mRNA Vaccine Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By mRNA Type
        • 8.3.5.2.2. By Application

9. Asia-Pacific mRNA Vaccine Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By mRNA Type (Nucleoside-modified mRNA, Unmodified mRNA, Self-Amplifying mRNA)
    • 9.2.2. By Application (COVID-19 mRNA Vaccines, Non COVID-19 mRNA Vaccines, Others)
    • 9.2.3. By Country
  • 9.3. Asia-Pacific: Country Analysis
    • 9.3.1. China mRNA Vaccine Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By mRNA Type
        • 9.3.1.2.2. By Application
    • 9.3.2. India mRNA Vaccine Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By mRNA Type
        • 9.3.2.2.2. By Application
    • 9.3.3. Japan mRNA Vaccine Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By mRNA Type
        • 9.3.3.2.2. By Application
    • 9.3.4. South Korea mRNA Vaccine Market Outlook
      • 9.3.4.1. Market Size & Forecast
        • 9.3.4.1.1. By Value
      • 9.3.4.2. Market Share & Forecast
        • 9.3.4.2.1. By mRNA Type
        • 9.3.4.2.2. By Application
    • 9.3.5. Australia mRNA Vaccine Market Outlook
      • 9.3.5.1. Market Size & Forecast
        • 9.3.5.1.1. By Value
      • 9.3.5.2. Market Share & Forecast
        • 9.3.5.2.1. By mRNA Type
        • 9.3.5.2.2. By Application

10. South America mRNA Vaccine Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By mRNA Type (Nucleoside-modified mRNA, Unmodified mRNA, Self-Amplifying mRNA)
    • 10.2.2. By Application (COVID-19 mRNA Vaccines, Non COVID-19 mRNA Vaccines, Others)
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil mRNA Vaccine Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By mRNA Type
        • 10.3.1.2.2. By Application
    • 10.3.2. Argentina mRNA Vaccine Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By mRNA Type
        • 10.3.2.2.2. By Application
    • 10.3.3. Colombia mRNA Vaccine Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By mRNA Type
        • 10.3.3.2.2. By Application

11. Middle East and Africa mRNA Vaccine Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By mRNA Type (Nucleoside-modified mRNA, Unmodified mRNA, Self-Amplifying mRNA)
    • 11.2.2. By Application (COVID-19 mRNA Vaccines, Non COVID-19 mRNA Vaccines, Others)
    • 11.2.3. By Country
  • 11.3. MEA: Country Analysis
    • 11.3.1. South Africa mRNA Vaccine Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By mRNA Type
        • 11.3.1.2.2. By Application
    • 11.3.2. Saudi Arabia mRNA Vaccine Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By mRNA Type
        • 11.3.2.2.2. By Application
    • 11.3.3. UAE mRNA Vaccine Market Outlook
      • 11.3.3.1. Market Size & Forecast
        • 11.3.3.1.1. By Value
      • 11.3.3.2. Market Share & Forecast
        • 11.3.3.2.1. By mRNA Type
        • 11.3.3.2.2. By Application

12. Market Dynamics

  • 12.1. Drivers
  • 12.2. Challenges

13. Market Trends & Developments

  • 13.1. Recent Developments
  • 13.2. Merger Acquisition
  • 13.3. Product launches

14. Global mRNA Vaccine Market: SWOT Analysis

15. Porter's Five Forces Analysis

  • 15.1. Competition in the Industry
  • 15.2. Potential of New Entrants
  • 15.3. Power of Suppliers
  • 15.4. Power of Customers
  • 15.5. Threat of Substitute Products

16. Competitive Landscape

  • 16.1. Business Overview
  • 16.2. Product Offerings
  • 16.3. Recent Developments
  • 16.4. Financials (As Reported)
  • 16.5. Key Personnel
  • 16.6. SWOT Analysis
    • 16.6.1. Arcturus Therapeutics Holdings Inc.
    • 16.6.2. BioNTech SE
    • 16.6.3. CureVac N.V.
    • 16.6.4. Daiichi Sankyo Company Limited.
    • 16.6.5. Ethris GmbH
    • 16.6.6. GlaxoSmithKline plc
    • 16.6.7. Gennova Biopharmaceuticals Ltd
    • 16.6.8. Moderna, Inc.
    • 16.6.9. Pantherna Therapeutics GmbH
    • 16.6.10. Providence Therapeutics
    • 16.6.11. Silence Therapeutics
    • 16.6.12. Translate Bio
    • 16.6.13. VERSAMEB AG
    • 16.6.14. Verve Therapeutics Inc.

17. Strategic Recommendations